PEPITEM Peptide: New Research on Arthritis and Autoimmune Disease

PEPITEM was first identified in 2014 by researchers studying how the immune system controls the movement of white blood cells into inflamed tissues. The name stands for “PEptide associated with PImodules of adiponecTin.“ It is produced by white blood cells in response to adiponectin, a hormone released by fat tissue. For years, PEPITEM was mainly of interest to immunologists studying basic immune regulation. That changed in early 2026 when Professor Helen McGettrick's team at the University of Birmingham, working with collaborators at the University of Federico III in Naples, published the first study showing PEPITEM could treat active inflammatory arthritis in animal models. The study appeared in Arthritis and Rheumatology, the journal of the American College of Rheumatology. It got picked up by the Daily Mail, ScienceDaily, and several medical news outlets. The reason is simple: PEPITEM worked as well as infliximab in mice, and infliximab is one of the most widely used biologic drugs for rheumatoid arthritis.

Your immune system uses white blood cells to fight infection and heal injuries. When those cells move into joints or other tissues in large numbers, they cause inflammation. In healthy people, adiponectin signals white blood cells to produce PEPITEM, which acts as a brake on this process. It limits how many immune cells enter the tissue and how aggressive their inflammatory response is. In people with inflammatory arthritis, this braking system fails. Their white blood cells stop responding properly to adiponectin. They produce less PEPITEM. Without that brake, immune cells flood into the joints, release inflammatory chemicals (NF-kB, COX2), and cause the swelling, pain, and tissue damage that characterize rheumatoid and psoriatic arthritis. Synthetic PEPITEM restores the brake. When researchers injected it into mice with active arthritis, it reduced inflammatory mediators in the joint tissue, increased the production of regulatory T cells (the immune cells that suppress excessive inflammation), and reversed the physical signs of disease. What makes PEPITEM different from drugs like infliximab or methotrexate is that it works with the body's own immune regulation system rather than suppressing the immune system broadly. Infliximab blocks TNF-alpha, a specific inflammatory signal. PEPITEM restores a regulatory pathway that prevents immune cells from getting out of control in the first place.

In the Birmingham study, PEPITEM did several things in mouse models of inflammatory and gouty arthritis:

• Prevented the onset of inflammatory arthritis when given before disease developed
• Reduced disease severity in mice that already had active arthritis
• Downregulated NF-kB and COX2 protein in joint tissue
• Increased foxp3 transcript, which is needed for regulatory T cell development
• Reduced white blood cell infiltration into the synovial membrane

Separate research has also shown that PEPITEM could protect against “inflammageing,“ the chronic low-grade inflammation that accumulates with age. Older individuals produce less PEPITEM, which may contribute to higher rates of autoimmune disease and inflammatory conditions in older adults. The infliximab comparison is significant. In the animal model, PEPITEM produced reductions in inflammation that were comparable to infliximab at standard doses. This does not mean PEPITEM will work the same way in humans, but it is a strong signal.

PEPITEM is not available as a therapy yet, so there are no patient testimonials. However, people with inflammatory arthritis who follow peptide research have been discussing it on Reddit and in online communities since the April 2026 study came out. A user on r/Peptides wrote, “If PEPITEM works even half as well in humans as it did in those mice, it would be the biggest thing in rheumatology in 20 years. Infliximab works but it wrecks your immune system. Something that restores natural regulation instead of suppressing everything is a completely different approach.“ Another user on r/Rheumatoid noted, “My rheumatologist mentioned PEPITEM at my last appointment. She said it is years away from being prescribed but the mechanism makes sense. The fact that it works with regulatory T cells instead of just blocking inflammation gives her hope.“

PEPITEM is still in preclinical and early clinical development. If it reaches the market, the expected benefits based on current research are:

• Reduced joint inflammation without broad immune suppression
• Lower risk of infections compared to biologic drugs like infliximab
• Potential to prevent arthritis onset in high-risk individuals
• May work for multiple types of inflammatory arthritis (rheumatoid, psoriatic, gouty)
• Could address inflammageing in older adults
• Restoration of the body's own immune regulation rather than adding another suppressive drug

PEPITEM is not yet available for clinical use. However, people managing autoimmune and inflammatory conditions currently use other peptides that target related pathways:

• Thymosin Alpha-1 for immune modulation and balancing T cell responses
• BPC-157 for its anti-inflammatory effects and tissue repair, particularly in the gut (which plays a role in autoimmune disease)
• KPV for reducing inflammation at the gut level, where immune dysregulation often originates
• GHK-Cu for tissue repair and its anti-inflammatory properties
• TB-500 for reducing systemic inflammation and supporting tissue repair

These are used under physician supervision for autoimmune-related symptoms today. PEPITEM may eventually join this list once clinical trials are complete.